DNDi trial raises prospect of cut-price HCV drugs in Malaysia

The Drugs for Neglected Diseases initiative (DNDi) says results from its Phase II/III STORM-C-1 trial of a sofosbuvir/ravidasvir combination, produced by Egyptian generic drugmaker Pharco Pharmaceuticals, shows the hepatitis C therapy to be “safe and effective, with extremely high cure rates for patients, including hard-to-treat cases.”

Founded in 2003, the Geneva-based non-profit conducts its own clinical development programs drawing from a mix of public and private donations. The group has a pipeline of over 30 projects targeting some of the world’s most neglected diseases.

In accordance with international standards defining cure for HCV treatments, 12 weeks after treatment completion, 97% of those enrolled were cured, and no new safety signals were detected.